How it works, simply
It supplies a growth signal that is insufficient in the indicated population.
What the evidence tells us
It is not a general muscle-building medicine; the diagnostic criteria and risks are specific.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Severe hypoglycemia is an important risk.
- Intracranial hypertension and growth of lymphoid tissue are also described in the label.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates the IGF-1 receptor to support growth in a narrowly defined deficiency population.
Sponsor or developer: Ipsen
Studied or labeled topics: Severe primary IGF-1 deficiency
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: INCRELEX prescribing information ↗ · Regulator · May 20, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.